Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.5775 | 0.5775 |
Onchocerca volvulus | 0.0033 | 0.387 | 0.5 | |
Onchocerca volvulus | 0.0033 | 0.387 | 0.5 | |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0871 | 0.1977 |
Schistosoma mansoni | lamin | 0.0033 | 0.387 | 0.6116 |
Echinococcus granulosus | GPCR family 2 | 0.0019 | 0.0871 | 0.1977 |
Echinococcus granulosus | lamin | 0.0033 | 0.387 | 1 |
Echinococcus multilocularis | GPCR, family 2 | 0.0019 | 0.0871 | 0.1977 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.387 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0132 | 0.0132 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.387 | 0.3537 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.387 | 0.387 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.5775 | 0.5545 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0019 | 0.0871 | 0.0871 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.3738 | 0.3738 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 1 | 1 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0871 | 0.1977 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0871 | 0.1977 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.387 | 0.387 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.387 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.387 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 1 | 1 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0516 | 0.0516 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0019 | 0.0871 | 0.0375 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 0.387 | 0.6116 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0871 | 0.0871 |
Echinococcus multilocularis | lamin | 0.0033 | 0.387 | 1 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0019 | 0.0871 | 0.0375 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.387 | 0.387 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.387 | 0.3537 |
Echinococcus multilocularis | musashi | 0.0033 | 0.387 | 1 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0871 | 0.1977 |
Schistosoma mansoni | lamin | 0.0033 | 0.387 | 0.6116 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.5775 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.2936 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 0.4467 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.3115 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 6.3096 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 11.2202 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.